SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

Italian ophthalmic company SIFI announced it has entered into a strategic multi-year agreement with Bausch Health Russia to market its products treating ophthalmic disorders in Russia.

Terms of the deal were not disclosed.

Initial sales are expected in 2021, marketing 5 SIFI products, including:

– Colbiocin, Nettavisc, and Nettacin: antibiotic solutions indicated for the treatment of external eye infections and available in multiple dosage forms;

– Octilia: an eye-drop solution indicated for the treatment of irritations, reddening, ocular congestion and itching due to allergic, chemical or physical causes;

– Mirtilene Forte Capsules: a retinotrophic vasoprotective food supplement, helpful in cases of capillary fragility or vascular alterations due to diabetic retinopathy.

Bausch Health Russia will have the option to commercialize future SIFI products currently under development.

“SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health Russia,” Gilberto Dalesio, SIFI’s CCO, said in a company news release. “By joining forces SIFI will strengthen its global footprint and establish its presence in Russia, one of the fastest growing pharmaceutical markets in the world, and will enable Russian eye care doctors to address a wide variety of ophthalmic disorders, delivering significant benefits to Russian patients.”  

“Bausch Health is pleased to partner with SIFI, because together we can ensure Russian eye health doctors and their patients have greater access to these important ophthalmic medications,” said Cees Heiman, Vice President Europe/Russia Pharmaceuticals, Bausch Health.